advertisement

WGA Rescources

Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 16

Showing records 1 to 16 | Display all abstracts in Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie

117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Wu LH
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Liao J; Lai Z
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Cheng YW
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Huang G
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Lin FL; Hsu KC
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Lin J
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Wang MH
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Huang W; Qin Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Yen JL; Wang TJ
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Chen Q
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Lin TE
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Hu Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Liu YC
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Cheng Q; Jiang L
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042
117976 A novel HDAC8 inhibitor H7E exerts retinoprotective effects against glaucomatous injury via ameliorating aberrant Müller glia activation and oxidative stress
Huang WJ; Hsiao G
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 174: 116538
118313 Setanaxib mitigates oxidative damage following retinal ischemia-reperfusion via NOX1 and NOX4 inhibition in retinal ganglion cells
Cui L; Zhong H; Li M; Wei Y; Xu F
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2024; 170: 116042

Issue 24-4

Change Issue


advertisement

Topcon